Trial Profile
A case-control study evaluating the efficacy and safety of combined therapy with pirfenidone and inhaled N-acetylcysteine for idiopathic pulmonary fibrosis.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 03 May 2019
Price :
$35
*
At a glance
- Drugs Acetylcysteine (Primary) ; Pirfenidone (Primary)
- Indications Idiopathic pulmonary fibrosis
- Focus Therapeutic Use
- 31 Dec 2014 New trial record